Oppenheimer analyst Michael Wiederhorn published a report on HCA Inc. HCA that reiterated its Outperform rating and raised the price target from $43 to $48.
Oppenheimer reported that, “Our 12- to 18-month price target is $48 per share, or an average of 7x '14E EBITDA of $6.8B, which is a discount to the historical
industry average of 8.5X. We believe this discount is even more conservative when considering it does not include any potential upside
to earnings from healthcare reform in 2015 and 2016.”
Shares of HCA Inc. closed at $38.56 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in